EP Patent
EP2451482B1 — Combination therapy for the treatment of diabetes
Assigned to Janssen Pharmaceutica NV · Expires 2019-05-01 · 7y expired
What this patent protects
Patent listed against Invokana.
Drugs covered by this patent
- Invokana (CANAGLIFLOZIN) · Johnson & Johnson
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.